BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Bristol-Myers Squibb Company (NYSE: BMY)
›
Bristol-Myers Squibb Company (NYSE: BMY) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 32,500 employees.
The shares were at 58.83 USD on 20 November 2026, up 28.5% over 52 weeks. Its 52-week range is 45.27 USD to 68.64 USD: the price is 14.3% below the high and 30.0% above the low.
At a market capitalisation of 120.25B USD, it trades at 13.0 times trailing earnings and 8.8 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.9, a discount of 50% for BMY. It pays a dividend yielding 4.32% (it pays out 56% of its earnings), against a median of 2.45% among the dividend payers in that peer group.
Bristol-Myers Squibb Company reports return on equity of 38.2%, an operating margin of 32.4% and revenue up 6.9% year over year.
Its debt exceeds its cash by 32.23B USD, a debt-to-equity ratio of 2.55. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 24 analysts cover the stock, with an average rating of Hold; their mean price target of 65.25 USD is 10.9% above the current price. The next earnings report is expected on 4 February 2027.